Jazz Pharmaceuticals (NASDAQ:JAZZ)‘s stock had its “buy” rating reaffirmed by equities research analysts at B. Riley in a research note issued to investors on Tuesday. They presently have a $206.00 target price on the specialty pharmaceutical company’s stock. B. Riley’s target price suggests a potential upside of 51.75% from the stock’s current price.

A number of other research analysts have also recently weighed in on the company. Mizuho lifted their target price on Jazz Pharmaceuticals from $144.00 to $150.00 and gave the company a “neutral” rating in a report on Tuesday. Cantor Fitzgerald reiterated a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Sunday. Zacks Investment Research cut Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, November 10th. HC Wainwright reiterated a “neutral” rating and issued a $150.00 target price (up previously from $144.00) on shares of Jazz Pharmaceuticals in a report on Friday, November 10th. Finally, UBS reduced their target price on Jazz Pharmaceuticals from $172.00 to $168.00 and set a “buy” rating on the stock in a report on Wednesday, November 8th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and nineteen have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $181.28.

Shares of Jazz Pharmaceuticals (NASDAQ JAZZ) traded down $0.81 during trading on Tuesday, reaching $135.75. The company had a trading volume of 451,300 shares, compared to its average volume of 508,983. Jazz Pharmaceuticals has a 52-week low of $99.28 and a 52-week high of $163.75. The firm has a market capitalization of $8,186.84, a PE ratio of 17.13, a P/E/G ratio of 0.88 and a beta of 0.98. The company has a quick ratio of 2.94, a current ratio of 3.10 and a debt-to-equity ratio of 0.63.

In other news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $153.52, for a total transaction of $153,520.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Patrick G. Enright sold 352 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, November 17th. The stock was sold at an average price of $133.19, for a total value of $46,882.88. Following the sale, the director now directly owns 1,365 shares in the company, valued at $181,804.35. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 10,352 shares of company stock worth $1,417,763. Corporate insiders own 4.30% of the company’s stock.

A number of institutional investors have recently made changes to their positions in JAZZ. Janus Henderson Group PLC increased its holdings in Jazz Pharmaceuticals by 11,990.7% in the second quarter. Janus Henderson Group PLC now owns 873,919 shares of the specialty pharmaceutical company’s stock valued at $135,894,000 after buying an additional 866,691 shares during the last quarter. FMR LLC increased its holdings in Jazz Pharmaceuticals by 11.4% in the second quarter. FMR LLC now owns 8,290,410 shares of the specialty pharmaceutical company’s stock valued at $1,289,159,000 after buying an additional 849,348 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Jazz Pharmaceuticals by 41.2% in the second quarter. JPMorgan Chase & Co. now owns 1,405,408 shares of the specialty pharmaceutical company’s stock valued at $218,540,000 after buying an additional 410,031 shares during the last quarter. Schroder Investment Management Group bought a new stake in Jazz Pharmaceuticals in the third quarter valued at about $52,571,000. Finally, American Century Companies Inc. increased its holdings in Jazz Pharmaceuticals by 133.2% in the second quarter. American Century Companies Inc. now owns 549,900 shares of the specialty pharmaceutical company’s stock valued at $85,509,000 after buying an additional 314,094 shares during the last quarter. 91.30% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “B. Riley Reaffirms Buy Rating for Jazz Pharmaceuticals (JAZZ)” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2017/12/06/b-riley-reaffirms-buy-rating-for-jazz-pharmaceuticals-jazz.html.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.